GLP-1 drugs like semaglutide (Ozempic) and tirzepatide (Mounjaro) may shrink fat, but also crucial muscle mass, with little evidence of improving cardiorespiratory fitness, researchers say.

More data, this time from a large observational study, are bolstering the idea that glucagon-like peptide-1 (GLP-1) receptor ...

DR NELLY KAMWALEKenya’s healthcare system is witnessing a quiet transformation with the introduction of newer therapies for managing Type 2 diabetes and obesity. Two drugs, Semaglutide and Tirzepatide ...

Healthcare professionals are calling for a fundamental shift in public perception around medically supervised weight loss ...

Tirzepatide improves outcomes in patients with obesity-related HFpEF regardless of the severity of their baseline BMI or fat ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Hormone therapy as an adjunctive to tirzepatide was associated with greater weight loss than tirzepatide alone among postmenopausal women.

Binge eating disorder is strongly associated with weight gain and obesity, though not all individuals with obesity have BED.

GLP-1 receptor agonists semaglutide and tirzepatide are associated with reduced risks of dementia, stroke, and mortality in ...

A new study has found that a drug used for treating obesity and type 2 diabetes may also help slow the growth of breast cancer caused by obesity.

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.